Neurocrine Biosciences, Inc.

NBIX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $3.0M
Cost of Revenue —
Gross Profit —
Gross Margin —
Operating Expenses
Research & Development $33.7M
SG&A Expense $14.4M
Operating Income $-53.7M
Operating Margin -1,817.5%
Interest Expense —
Pretax Income —
Income Tax Expense —
Net Income $-51.0M
Net Margin -1,728.3%
EPS (Basic) $-1.30
EPS (Diluted) $-1.30
Shares Outstanding (Basic) 39.1M
Shares Outstanding (Diluted) 39.1M
Dividends Per Share —
← Newer Page 3 of 3 Older →